GH RESEARCH PLC DL-025 (1KA) - Total Assets
Based on the latest financial reports, GH RESEARCH PLC DL-025 (1KA) holds total assets worth €372.35 Million EUR (≈ $435.32 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GH RESEARCH PLC DL-025 cash conversion from operations for how efficiently the company converts equity into cash flow.
GH RESEARCH PLC DL-025 - Total Assets Trend (2021–2025)
This chart illustrates how GH RESEARCH PLC DL-025's total assets have evolved over time, based on quarterly financial data. See 1KA share price today for real-time trading data and today's change.
GH RESEARCH PLC DL-025 - Asset Composition Analysis
Current Asset Composition (December 2025)
GH RESEARCH PLC DL-025's total assets of €372.35 Million consist of 99.2% current assets and 0.8% non-current assets. Explore GH RESEARCH PLC DL-025 (1KA) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 85.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how GH RESEARCH PLC DL-025's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GH RESEARCH PLC DL-025's current assets represent 99.2% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 85.4% of total assets in 2025, down from 98.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GH RESEARCH PLC DL-025 Competitors by Total Assets
Key competitors of GH RESEARCH PLC DL-025 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Seegene Inc
KQ:096530
|
Korea | ₩1.27 Trillion |
GH RESEARCH PLC DL-025 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.70 | 29.49 | 15.83 |
| Quick Ratio | 28.70 | 29.49 | 15.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €355.97 Million | €283.91 Million | €145.16 Million |
GH RESEARCH PLC DL-025 - Advanced Valuation Insights
This section examines the relationship between GH RESEARCH PLC DL-025's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.90 |
| Latest Market Cap to Assets Ratio | 4.24 |
| Asset Growth Rate (YoY) | 53.1% |
| Total Assets | €288.23 Million |
| Market Capitalization | $1.22 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values GH RESEARCH PLC DL-025's assets at a significant premium (4.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: GH RESEARCH PLC DL-025's assets grew by 53.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GH RESEARCH PLC DL-025 (2021–2025)
The table below shows the annual total assets of GH RESEARCH PLC DL-025 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €288.23 Million ≈ $336.97 Million |
+53.09% |
| 2024-12-31 | €188.27 Million ≈ $220.11 Million |
-16.80% |
| 2023-12-31 | €226.30 Million ≈ $264.57 Million |
-11.03% |
| 2022-12-31 | €254.36 Million ≈ $297.38 Million |
-9.13% |
| 2021-12-31 | €279.92 Million ≈ $327.26 Million |
-- |
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more